The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?

Health Policy

Volumn 95, Issue 2-3, 2010, Pages 216-228

  Wellman Labadie, Olivier ^a   Zhou, Youwen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Blockbuster Drug; Health Technology Assessment; Healthcare Policy; Orphan drug; Orphan Drug Act; Rare disease

Indexed keywords

ARTICLE; BUSINESS ETHICS; COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH ECONOMICS; PROFIT; UNITED STATES;

ANNUAL REPORTS AS TOPIC; COMMERCE; DATABASES, FACTUAL; DRUG APPROVAL; DRUG INDUSTRY; HEALTH CARE REFORM; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MARKETING OF HEALTH SERVICES; MOTIVATION; ORGANIZATIONS; ORPHAN DRUG PRODUCTION; RARE DISEASES; RESEARCH SUPPORT AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VULNERABLE POPULATIONS;

EID: 77950937284     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2009.12.001     Document Type: Article

References (34)

1. Haffner M.E., Whitley J., Moses M. Two decades of orphan product development. Nature Reviews Drug Discovery 2002, 1:821-825.
2. Cheung R.Y., Cohen J.C., Illingworth P. Orphan drug policies: implications for the United States. Canada and developing countries. Health Law Journal 2004, 12:183-200.
3. Griggs R.C., Batshaw M., Dunkle M., Gopal-Srivastava R., Kaye E., Krischer J., et al. Clinical research for rare disease: opportunities, challenges and solutions. Molecular Genetics and Metabolism 2009, 96:20-26.
4. Lang J., Wood S.C. Development of orphan vaccines: an industry perspective. Emerging Infectious Diseases 1999, 5(6):749-755.
5. The Orphan Drug Act. Implementation and Impact. United States Department of Health and Human Services. Office of Inspector General; May 2001. http://oig.hhs.gov/oei/o.asp%23orphan_drug.
6. Seoane-Vazquez E., Rodriguez-Monguio R., Szeinbach S.L., Visaria J. Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Diseases 2008, 3:33.
7. Rosenberg-Yunger Z.R.S., Daar A.S., Singer P.A., Martin D.K. Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada. Health Policy 2008, 87:359-368.
8. Yin W. Market incentives and pharmaceutical innovation. Journal of Health Economics 2008, 27:1060-1077.
9. Malik N.N. Biotech acquisitions by big pharma: why and what is next. Drug Discovery Today 2009, 14(17/18):818-821.
10. Golec J., Vernon J.A. Financial risk of the biotech industry versus the pharmaceutical industry. Applied Health Economics and Health Policy 2009, 7(3):155-165.
11. Villa S., Compagni A., Reich M.R. Orphan drug legislation: lessons for neglected tropical diseases. International Journal of Health Planning and Management 2009, 24:27-42.
12. Seachrist L. Senators seek reform of orphan drug act. Journal of the National Cancer Institute 1993, 85(24):1984-1985.
13. Gershon D. Bush veto fuels orphan drug act uncertainties. Nature 1990, 348:185.
14. Lawrence S. Biotech patents-business as usual?. Nature Biotechnology 2009, 26(12):1326.
15. Pharmaceutical trends. Top pharmaceutical markets worldwide 2008. IMS Health Canada; 2009. http://us.imshealth.com/canada/Trends16_En_09.pdf.
16. Casali P.G. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology. Annals of Oncology 2007, 18:1923-1925.
17. Gavel S.J. The oncology pipeline: maturing, competitive, and growing?. Oncology Business Review 2008, (September):14-16.
18. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286(5439):531-537.
19. Haffner M.E., Torrent-Farneli J., Maher P.D. Does orphan drug legislation really answer the needs of patients?. Lancet 2008, 371:2041-2044.
20. Borda C. 25 years of the Orphan Drug Act. PharmaVoice; April 2008. [accessed April 17, 2009]. http://www.pharmavoice.com/.
21. Blockbuster Drugs 2006. 2006 Sales of 114 Blockbuster Drugs. R&D Pipeline News. La Merie Business Intelligence; 24 July 2007. [accessed April 17, 2009]. http://www.pipelinereview.com/index.php/2007072515650/FREE-Reports/Blockbuster-Drugs-2006-2006-Sales-of-114-Blockbuster-Drugs.html.
22. Lee T.H., Emanuel E.J. Tier 4 drugs and the fraying of the social compact. New England Journal of Medicine 2008, 359(4):333-335.
23. Thamer M., Brennan N., Semansky R. A cross-national comparison of orphan drug policies: implications for the U.S. orphan drug act. Journal of Health Politics and Law 1998, 23(2):265-290.
24. Huttin C. Drug price divergence in Europe: regulatory aspects. Health Affairs 1999, 18(3):245-249.
25. Gericke C.A., Riesberg A., Busse R. Ethical issues in funding orphan drug research and development. Journal of Medical Ethics 2005, 31:164-168.
26. Scharf S. Orphan drugs: the question of product liability. American Journal of Law and Medicine 1985, 10(4):491-513.
27. Lexchin J. Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. Canadian Medical Association Journal 2006, 174(8):1120-1121.
28. Vernon J.A., Golec J.H., Hughen W.K. The economics of pharmaceutical price regulation and importation: refocusing the debate. American Journal of Law Medicine 2006, 32(2-3):175-192.
29. European prices of 170 best-selling drugs averaged 40 percent less than U.S. prices in 2008. 2009 Chartbook of international pharmaceutical prices. Decision Resources. http://www.decisionresources.com/EUROPEAN-PRICES-OF-170-BEST-SELLING-DRUGS-AVERAGED-40-PERCENT-LESS-THAN-U-S--PRICES-IN-2008.
30. Anand G. How drugs for rare diseases became lifeline for companies. The Wall Street Journal; November 1, 2005. [accessed April 17, 2009]. http://online.wsj.com/article/SB113202332063297223.html.
31. Aggarwal S. What's fueling the biotech engine-2007. Nature Biotechnology 2008, 26(11):1227-1233.
32. Aggarwal S. What's fueling the biotech engine?. Nature Biotechnology 2007, 25(10):1097-1104.
33. Canada's orphan drug policy. Learning from the Best. Canadian organisation for rare disorders; 2005. http://www.raredisorders.ca/documents/CanadaOrphanDPFinal.pdf.
34. Minghetti P., Giudici E.M., Montanari L. A proposal to improve the supply of orphan drugs. Pharmacological Research 2000, 42(1):33-37.